What is NDC 66993-783?

66993-783 is the product NDC for phentermine and topiramate, Phentermine hydrochloride 15 mg/1; Topiramate 92 mg/1 capsule, extended release, listed with the FDA by Prasco Laboratories. It has 1 package NDC, shown above in 10- and 11-digit form.

What is the active ingredient?

Phentermine hydrochloride, Topiramate.

Prasco Laboratories, NDC labeler code 66993. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for phentermine and topiramate?

5 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

phentermine and topiramate NDC 66993-783

NDC codes

FDA NDC Directory

Product NDC (as listed)66993-783Labeler and product segments. Claims need a package NDC.

Product NDC at billing width66993-0783Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
66993-783-30	6699307833066993078330	30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, UNIT-DOSE (66993-783-30)Marketed from Jun 1, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): phentermine and topiramate
Generic name (nonproprietary): phentermine and topiramate
Active ingredients: Phentermine hydrochloride — 15 mg/1Topiramate — 92 mg/1
Dosage form: Capsule, Extended release
Route: Oral
Labeler: Prasco LaboratoriesNDC labeler code 66993
Product type: Prescription drug
Marketing category: NDA authorized genericApplication NDA 022580
Marketing start: Jun 1, 2025
Listing expires: Dec 31, 2027
DEA schedule: CIV
Other FDA classes: Appetite Suppression (Physiologic effect)Cytochrome P450 2C19 Inhibitors (Mechanism)Cytochrome P450 3A4 Inducers (Mechanism)Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)Increased Sympathetic Activity (Physiologic effect)
Identifiers: Product ID 66993-783_52217277-c719-2f2f-e063-6394a90a6699SPL ID 52217277-c719-2f2f-e063-6394a90a6699SPL set ID 876bd763-13fa-481e-b579-c2fc44dbf3c2RxCUI 1302827, 1302839, 1302850, 1313059UNII 0K2I505OTV, 0H73WJJ391UPC 0366993783307, 0366993782300, 0366993781303, 0366993780306
Pharmacologic class: Sympathomimetic Amine Anorectic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N466993078330 followed by a unit qualifier and the quantity

Package 66993-0783-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 18, 2026.

Indications (excerpt from the label)

Phentermine and topiramate extended-release capsules are indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbid condition Limitations of Use The effect of phentermine and topiramate extended-release capsules on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of phentermine and topiramate extended-release capsules in combination with other products intended for weight loss, including prescription drugs,…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 66993-783

What is NDC 66993-783?: 66993-783 is the product NDC for phentermine and topiramate, Phentermine hydrochloride 15 mg/1; Topiramate 92 mg/1 capsule, extended release, listed with the FDA by Prasco Laboratories. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: phentermine and topiramate.
What is the active ingredient?: Phentermine hydrochloride, Topiramate.
Who is the labeler?: Prasco Laboratories, NDC labeler code 66993. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for phentermine and topiramate?: 5 other product NDCs are listed under this name. See all phentermine and topiramate NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other phentermine and topiramate NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
phentermine and topiramate	Phentermine hydrochloride 3.75 mg/1; Topiramate 23 mg/1	Capsule, Extended releaseOral	Prasco Laboratories	66993-780	66993-0780-30
phentermine and topiramate	Phentermine hydrochloride 7.5 mg/1; Topiramate 46 mg/1	Capsule, Extended releaseOral	Prasco Laboratories	66993-781	66993-0781-30
phentermine and topiramate	Phentermine hydrochloride 11.25 mg/1; Topiramate 69 mg/1	Capsule, Extended releaseOral	Prasco Laboratories	66993-782	66993-0782-30
Phentermine and topiramate	Phentermine hydrochloride 11.25 mg/1; Topiramate 69 mg/1	Capsule, Extended releaseOral	Teva Pharmaceuticals, Inc.	0480-2299	00480-2299-56
Phentermine and topiramate	Phentermine hydrochloride 15 mg/1; Topiramate 92 mg/1	Capsule, Extended releaseOral	Teva Pharmaceuticals, Inc.	0480-3295	00480-3295-56

Other NDCs under NDA 022580

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 022580
Product	Strength	Form · route	Labeler	Product NDC
phentermine and topiramate	Phentermine hydrochloride 3.75 mg/1; Topiramate 23 mg/1	Capsule, Extended releaseOral	Prasco Laboratories	66993-780
phentermine and topiramate	Phentermine hydrochloride 7.5 mg/1; Topiramate 46 mg/1	Capsule, Extended releaseOral	Prasco Laboratories	66993-781
phentermine and topiramate	Phentermine hydrochloride 11.25 mg/1; Topiramate 69 mg/1	Capsule, Extended releaseOral	Prasco Laboratories	66993-782
Qsymiaphentermine and topiramate	Phentermine hydrochloride 3.75 mg/1; Topiramate 23 mg/1	Capsule, Extended releaseOral	Vivus LLC	62541-201
Qsymiaphentermine and topiramate	Phentermine hydrochloride 7.5 mg/1; Topiramate 46 mg/1	Capsule, Extended releaseOral	Vivus LLC	62541-202
Qsymiaphentermine and topiramate	Phentermine hydrochloride 11.25 mg/1; Topiramate 69 mg/1	Capsule, Extended releaseOral	Vivus LLC	62541-203
Qsymiaphentermine and topiramate	Phentermine hydrochloride 15 mg/1; Topiramate 92 mg/1	Capsule, Extended releaseOral	Vivus LLC	62541-204